Depression is a serious medical condition that affects hundreds of thousands of Americans. Ketamine and recently some metabolites of ketamine have been reported to have unique antidepressant activity in humans and mouse models. Here, we report the full synthesis of known ketamine metabolites and assess their activity against the N-methyl-D-aspartate receptor, the primary pharmacological target of ketamine. With this data, we hope to help further the development of ketamine metabolites as potential treatments for depression.

Synthesis and NMDA receptor activity of various ketamine metabolites

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.